Published in Cardiol Rev on February 09, 2004
Aerobic interval training vs. continuous moderate exercise in the metabolic syndrome of rats artificially selected for low aerobic capacity. Cardiovasc Res (2008) 1.37
High-Density Lipoprotein (HDL) Phospholipid Content and Cholesterol Efflux Capacity Are Reduced in Patients With Very High HDL Cholesterol and Coronary Disease. Arterioscler Thromb Vasc Biol (2015) 0.84
Low HDL cholesterol, smoking and IL-13 R130Q polymorphism are associated with myocardial infarction in Greek Cypriot males. A pilot study. Open Cardiovasc Med J (2008) 0.77
Statin-associated myopathy. JAMA (2003) 7.22
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol (2007) 4.93
Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol (2004) 4.62
Molecular and cellular basis of cardiovascular gender differences. Science (2005) 4.37
Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. Am Heart J (2003) 3.73
Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J (2010) 3.22
Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol (2008) 2.77
Enhanced external counterpulsation improves endothelial function in patients with symptomatic coronary artery disease. J Am Coll Cardiol (2003) 2.52
Abnormal vascular function and hypertension in mice deficient in estrogen receptor beta. Science (2002) 2.45
Association between statin-associated myopathy and skeletal muscle damage. CMAJ (2009) 2.41
Regulator of G-protein signaling-2 mediates vascular smooth muscle relaxation and blood pressure. Nat Med (2003) 2.33
Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab (2010) 2.27
The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation (2005) 2.19
Estrogen receptor inhibits mineralocorticoid receptor transcriptional regulatory function. Endocrinology (2014) 2.17
Effect of soy protein from differently processed products on cardiovascular disease risk factors and vascular endothelial function in hypercholesterolemic subjects. Am J Clin Nutr (2007) 2.15
Association between estrogen receptor alpha gene variation and cardiovascular disease. JAMA (2003) 2.10
HRT and the young at heart. N Engl J Med (2007) 2.07
Estrogen receptor-alpha mediates the protective effects of estrogen against vascular injury. Circ Res (2002) 2.05
Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol (2010) 1.95
Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med (2007) 1.88
Rapid estrogen receptor signaling is essential for the protective effects of estrogen against vascular injury. Circulation (2012) 1.78
Striatin assembles a membrane signaling complex necessary for rapid, nongenomic activation of endothelial NO synthase by estrogen receptor alpha. Proc Natl Acad Sci U S A (2004) 1.77
Variation in estrogen-related genes and cross-sectional and longitudinal blood pressure in the Framingham Heart Study. J Hypertens (2005) 1.77
What is the best approach for the assessment of left atrial size? Comparison of various unidimensional and two-dimensional parameters with three-dimensional echocardiographically determined left atrial volume. J Am Soc Echocardiogr (2006) 1.76
17beta-estradiol reduces cardiomyocyte apoptosis in vivo and in vitro via activation of phospho-inositide-3 kinase/Akt signaling. Circ Res (2004) 1.74
Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society. Menopause (2008) 1.74
Clinical utility of endothelial function testing: ready for prime time? Circulation (2003) 1.62
Ventricular assist device therapy normalizes inducible nitric oxide synthase expression and reduces cardiomyocyte apoptosis in the failing human heart. J Am Coll Cardiol (2005) 1.61
Mechanically unloading the left ventricle before coronary reperfusion reduces left ventricular wall stress and myocardial infarct size. Circulation (2013) 1.58
Effects of statins on vascular structure and function: a systematic review. Am J Med (2004) 1.57
Statins and interstitial lung disease: a systematic review of the literature and of food and drug administration adverse event reports. Chest (2008) 1.51
Statin use is associated with enhanced collateralization of severely diseased coronary arteries. Am Heart J (2003) 1.51
High-density lipoproteins: a consensus statement from the National Lipid Association. J Clin Lipidol (2013) 1.50
High blood pressure arising from a defect in vascular function. Proc Natl Acad Sci U S A (2008) 1.50
Renal actions of RGS2 control blood pressure. J Am Soc Nephrol (2010) 1.48
Estrogen receptors alpha and beta mediate distinct pathways of vascular gene expression, including genes involved in mitochondrial electron transport and generation of reactive oxygen species. Mol Endocrinol (2007) 1.47
Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant (2011) 1.47
Comparison of the safety and efficacy of a combination tablet of niacin extended release and simvastatin vs simvastatin monotherapy in patients with increased non-HDL cholesterol (from the SEACOAST I study). Am J Cardiol (2008) 1.43
Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol (2002) 1.43
Comparison of the frequency of adverse events in patients treated with atorvastatin or simvastatin. Am J Cardiol (2003) 1.42
Relation of pulse pressure to blood pressure response to exercise in patients with hypertrophic cardiomyopathy. Am J Cardiol (2010) 1.41
Vascular endothelial dysfunction is associated with reversible myocardial perfusion defects in the absence of obstructive coronary artery disease. J Nucl Cardiol (2006) 1.41
Meta-analysis: statin therapy does not alter the association between low levels of high-density lipoprotein cholesterol and increased cardiovascular risk. Ann Intern Med (2010) 1.34
A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J (2002) 1.33
Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med (2003) 1.28
Estrogen attenuates left ventricular and cardiomyocyte hypertrophy by an estrogen receptor-dependent pathway that increases calcineurin degradation. Circ Res (2008) 1.26
Estrogen-induced smooth muscle cell growth is regulated by tuberin and associated with altered activation of platelet-derived growth factor receptor-beta and ERK-1/2. J Biol Chem (2004) 1.19
Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease. Am J Cardiol (2006) 1.19
A call to action: women and peripheral artery disease: a scientific statement from the American Heart Association. Circulation (2012) 1.19
Estrogen receptor-alpha variants are associated with lipoprotein size distribution and particle levels in women: the Framingham Heart Study. Atherosclerosis (2005) 1.13
Hormone replacement therapy and the cardiovascular system lessons learned and unanswered questions. J Am Coll Cardiol (2006) 1.12
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation (2012) 1.12
The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am Coll Cardiol (2012) 1.08
Echocardiographic characterization of left ventricular apical hypoplasia accompanied by a patent ductus arteriosus. Eur J Echocardiogr (2010) 1.07
Large brachial artery diameter is associated with angiographic coronary artery disease in women. Am Heart J (2002) 1.06
17-beta-estradiol increases cardiac remodeling and mortality in mice with myocardial infarction. J Am Coll Cardiol (2003) 1.05
Parasympathetic response in chick myocytes and mouse heart is controlled by SREBP. J Clin Invest (2008) 1.04
Risk of adverse events with fibrates. Am J Cardiol (2004) 1.03
Direct binding and regulation of RhoA protein by cyclic GMP-dependent protein kinase Iα. J Biol Chem (2012) 1.03
Uncorrected tetralogy of Fallot in an 86-year-old patient. Am J Geriatr Cardiol (2007) 1.02
17 Beta-estradiol differentially affects left ventricular and cardiomyocyte hypertrophy following myocardial infarction and pressure overload. J Card Fail (2008) 1.02
Relation between high-density lipoprotein cholesterol and peripheral vasomotor function. Am J Cardiol (2003) 1.01
Association of estrogen receptor beta gene polymorphisms with left ventricular mass and wall thickness in women. Am J Hypertens (2005) 1.00
Rapid progress for non-nuclear estrogen receptor signaling. J Clin Invest (2010) 1.00
Recent role of imaging in the diagnosis of pericardial disease. Curr Cardiol Rep (2002) 0.99
Protein kinase g iα inhibits pressure overload-induced cardiac remodeling and is required for the cardioprotective effect of sildenafil in vivo. J Am Heart Assoc (2012) 0.99
Protein phosphatase 2a (PP2A) binds within the oligomerization domain of striatin and regulates the phosphorylation and activation of the mammalian Ste20-Like kinase Mst3. BMC Biochem (2011) 0.99
Regulation of estrogen receptor alpha-mediated transcription by a direct interaction with protein phosphatase 2A. J Biol Chem (2002) 0.99
Extended-release niacin reduces LDL particle number without changing total LDL cholesterol in patients with stable CAD. J Clin Lipidol (2008) 0.99
High-density lipoprotein increases the abundance of eNOS protein in human vascular endothelial cells by increasing its half-life. J Am Coll Cardiol (2003) 0.98
Estrogen replacement and cardiomyocyte protection. Trends Cardiovasc Med (2006) 0.98
Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol (2007) 0.98
Augmentation index derived from peripheral arterial tonometry correlates with cardiovascular risk factors. Cardiol Res Pract (2011) 0.98
Left ventricular remodelling index (LVRI) in various pathophysiological conditions: a real-time three-dimensional echocardiographic study. Heart (2006) 0.97
Is the WHI relevant to HRT started in the perimenopause? Endocrine (2004) 0.97
Pre-operative left atrial mechanical function predicts risk of atrial fibrillation following cardiac surgery. JACC Cardiovasc Imaging (2011) 0.96
Rapid estrogen receptor signaling mediates estrogen-induced inhibition of vascular smooth muscle cell proliferation. Arterioscler Thromb Vasc Biol (2013) 0.95
Estrogen receptor-mediated regulation of microRNA inhibits proliferation of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol (2012) 0.94
Elevated augmentation index derived from peripheral arterial tonometry is associated with abnormal ventricular-vascular coupling. Clin Physiol Funct Imaging (2010) 0.94
MAP kinase mediates growth factor-induced nuclear translocation of estrogen receptor alpha. FEBS Lett (2002) 0.93
Role of SREBP-1 in the development of parasympathetic dysfunction in the hearts of type 1 diabetic Akita mice. Circ Res (2009) 0.93
Tendon rupture associated with simvastatin/ezetimibe therapy. Am J Cardiol (2007) 0.93
PDE5 inhibitor efficacy is estrogen dependent in female heart disease. J Clin Invest (2014) 0.92
Assessment of vascular endothelial function with peripheral arterial tonometry: information at your fingertips? Cardiol Rev (2009) 0.91
Differential regulation of the inducible nitric oxide synthase gene by estrogen receptors 1 and 2. J Endocrinol (2008) 0.89
RACK1 is a BKCa channel binding protein. Am J Physiol Cell Physiol (2006) 0.88
Transplantation and Mechanical Circulatory Support in Congenital Heart Disease: A Scientific Statement From the American Heart Association. Circulation (2016) 0.87